CD28 and lung cancer: Novel bio-nanocarriers composed of magnetic nanoparticles and fucoidan-dextran (IO- FuDex3) conjugated to T-cell activators (anti-CD28 and anti-CD3) or checkpoint inhibitors (anti-PD-L1) were developed and evaluated for their efficacy in lung cancer.